EMAIL THIS PAGE TO A FRIEND

Annales d'endocrinologie

Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.


PMID 23337021

Abstract

We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML0132
Lanreotide acetate, ≥98% (HPLC)
C54H69N11O10S2 · xC2H4O2